Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

0.5860 -0.0396 (-6.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 103,125
Open 0.6270
Bid (Size) 0.5852 (1)
Ask (Size) 0.6031 (8)
Prev. Close 0.6256
Today's Range 0.5739 - 0.6317
52wk Range 0.6010 - 5.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Via ACCESS Newswire

Performance

YTD
-57.8%
-57.8%
1 Month
-21.9%
-21.9%
3 Month
-56.6%
-56.6%
6 Month
-56.8%
-56.8%
1 Year
-78.5%
-78.5%

More News

Read More
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Dermata to Present on BioPub on January 31, 2025
Via ACCESS Newswire
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
Via ACCESSWIRE
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Via ACCESSWIRE
US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'
Via Benzinga
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
Which stocks are gapping on Thursday?
Via Chartmill
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
Via ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results
Via Benzinga
Top movers in Thursday's pre-market session
Via Chartmill
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne
Via Benzinga
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall
Via Benzinga
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Via ACCESS Newswire
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Via ACCESS Newswire
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
Via ACCESS Newswire
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for November 14th
From Virtual Investor Conferences
Via GlobeNewswire
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
From Virtual Investor Conferences
Via GlobeNewswire
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Via ACCESSWIRE
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE

Frequently Asked Questions

Is Dermata Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dermata Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dermata Therapeutics, Inc. - Common Stock trade on?
Dermata Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dermata Therapeutics, Inc. - Common Stock?
The ticker symbol for Dermata Therapeutics, Inc. - Common Stock is DRMA on the Nasdaq Stock Market
What is the current price of Dermata Therapeutics, Inc. - Common Stock?
The current price of Dermata Therapeutics, Inc. - Common Stock is 0.5860
When was Dermata Therapeutics, Inc. - Common Stock last traded?
The last trade of Dermata Therapeutics, Inc. - Common Stock was at 06/26/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.